Yatharth Hospital & Trauma Care Services Limited YATHARTH NSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.yatharthhospitals.com

Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surgery and liver transplant, robotic surgery, kidney transplant, IVF and fertility, emergency medicine, ophthalmology, dentistry, psychology and psychiatry, physiotherapy and rehabilitation, anesthesiology, radiology, pathology and laboratory medicine, nutrition and health, interventional spine and pain medicine, neurology, neurosurgery, and cardiovascular and thoracic surgery. In addition, the company sells medicines and canteen food. The company was incorporated in 2008 and is based in Noida, India.

Market & Price

Market Cap

₹7,674.62 Cr

Current Price

₹796.50

High / Low (52W)

₹862.20 / ₹500.35

Beta

1.12

Valuation

Stock P/E

43.86

Industry PE

37.60

Forward P/E

25.11

PEG Ratio

Book Value

₹175.25

Price to Book

4.54

P/S

6.22

EV/EBITDA

24.24

Dividend Yield

Profitability & Returns

ROCE

10.97%

ROE

9.89%

ROA

7.17%

Profit Margin

14.22%

Op Margin

14.61%

EPS (Latest Qtr)

₹4.93

EPS (TTM)

₹18.16

Balance Sheet & Liquidity

Debt/Equity

0.15

Quick Ratio

3.47

Current Ratio

3.87

Debt

₹264.09 Cr

Total Assets

₹2,281.53 Cr

Current Assets

₹712.02 Cr

Working Capital

₹528.13 Cr

Ownership

Promoter Holding

56.94%

Chg in Prom Hold

FII / Inst Holding

12.03%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹7,704.75 Cr

Total Revenue (TTM)

₹1,232.96 Cr

EBITDA

₹317.90 Cr

Free Cash Flow

₹-88.68 Cr

Operating Cash Flow

₹204.52 Cr

Shares Outstanding

₹9.64 Cr

Gross Margin

61.95%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

32.39%

Profit 5Y

38.67%

Revenue (YoY)

44.20%

Earnings (YoY)

12.90%

PROS

Compounding revenue at 32.4% over 5 years.
Profit CAGR of 38.7% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	YATHARTH Yatharth Hospital & Trauma Care Services Limited NSEPHARMA	796.50	43.86	₹7,674.62 Cr	-	10.97%	9.89%	32.39%	38.67%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	233.03 Cr	257.77 Cr	279.42 Cr	320.47 Cr	341.56 Cr
Cost of Revenue	-	-	88.21 Cr	53.51 Cr	56.40 Cr	62.46 Cr	132.28 Cr
Gross Profit	-	-	144.82 Cr	204.26 Cr	223.02 Cr	258.01 Cr	209.29 Cr
Operating Expenses	-	-	99.41 Cr	154.69 Cr	177.43 Cr	207.72 Cr	159.37 Cr
Operating Income	-	-	45.41 Cr	49.57 Cr	45.59 Cr	50.29 Cr	49.91 Cr
EBITDA	-	-	62.37 Cr	73.80 Cr	74.01 Cr	82.07 Cr	87.02 Cr
Interest Expense	-	-	97.20 L	19.00 L	25.70 L	1.02 Cr	5.07 Cr
Pretax Income	-	-	48.53 Cr	58.69 Cr	54.82 Cr	57.10 Cr	51.95 Cr
Tax Provision	-	-	9.81 Cr	16.65 Cr	13.57 Cr	14.01 Cr	7.25 Cr
Net Income	-	-	38.72 Cr	42.04 Cr	41.24 Cr	45.35 Cr	47.52 Cr
Diluted EPS	-	-	4.37	4.36	4.28	4.71	4.93

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	520.29 Cr	670.55 Cr	885.62 Cr	1,207.17 Cr
Cost of Revenue	-	92.94 Cr	133.31 Cr	338.92 Cr	469.15 Cr
Gross Profit	-	427.36 Cr	537.24 Cr	546.70 Cr	738.02 Cr
Operating Expenses	-	319.70 Cr	384.53 Cr	378.49 Cr	533.71 Cr
Operating Income	-	107.65 Cr	152.70 Cr	168.21 Cr	204.31 Cr
EBITDA	-	136.57 Cr	195.55 Cr	236.42 Cr	317.90 Cr
Interest Expense	-	21.39 Cr	9.42 Cr	7.51 Cr	6.54 Cr
Pretax Income	-	87.68 Cr	156.83 Cr	171.74 Cr	223.56 Cr
Tax Provision	-	21.91 Cr	42.36 Cr	41.19 Cr	53.26 Cr
Net Income	-	65.77 Cr	114.47 Cr	130.54 Cr	175.38 Cr
Diluted EPS	5.14	7.66	14.46	14.72	-

Compounded Sales Growth

5 Years:	32.39%
1 Year:	44.20%

Compounded Profit Growth

5 Years:	38.67%
1 Year:	12.90%

Stock Price Performance

1 Year:	+54.92%
6 Months:	+3.16%
3 Months:	+13.12%
1 Month:	-2.87%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	485.97 Cr	1,019.33 Cr	1,731.18 Cr	2,281.53 Cr
Current Assets	-	176.27 Cr	510.25 Cr	855.73 Cr	712.02 Cr
Cash & Equivalents	-	37.23 Cr	81.40 Cr	204.96 Cr	221.10 Cr
Inventory	-	6.07 Cr	8.13 Cr	20.95 Cr	20.67 Cr
Receivables	-	107.64 Cr	227.00 Cr	301.50 Cr	374.80 Cr
Total Liabilities	-	303.00 Cr	145.01 Cr	94.05 Cr	474.37 Cr
Current Liabilities	-	99.52 Cr	67.22 Cr	84.58 Cr	183.88 Cr
Long Term Debt	-	200.59 Cr	75.25 Cr	96.90 L	226.87 Cr
Total Debt	-	267.41 Cr	84.65 Cr	11.59 Cr	264.09 Cr
Total Equity	-	182.96 Cr	874.32 Cr	1,605.46 Cr	1,780.56 Cr
Shares Outstanding	-	8.59 Cr	8.59 Cr	9.64 Cr	9.64 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	63.78 Cr	-3.08 Cr	131.17 Cr	204.52 Cr
Investing Cash Flow	-	-20.31 Cr	-225.87 Cr	-387.58 Cr	-598.03 Cr
Financing Cash Flow	-	-17.75 Cr	304.21 Cr	509.09 Cr	253.53 Cr
Capital Expenditure	-	-19.81 Cr	-93.36 Cr	-301.93 Cr	-316.54 Cr
Free Cash Flow	-	43.97 Cr	-96.44 Cr	-170.75 Cr	-112.02 Cr
Net Change in Cash	-	25.73 Cr	75.26 Cr	252.69 Cr	-139.98 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	82.1%	80.1%	61.7%	61.1%
Operating Margin %	-	20.7%	22.8%	19.0%	16.9%
Net Margin %	-	12.6%	17.1%	14.7%	14.5%
ROE %	-	35.9%	13.1%	8.1%	9.8%
ROCE %	-	27.9%	16.0%	10.2%	9.7%

Shareholding Pattern

Insiders

56.94%

Institutions

12.03%

Public Float

27.93%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for YATHARTH

No recent headlines available.

YATHARTH · Healthcare